How many drugs treat Headache disorder?

Drug Landscape tracks 10 marketed treatments for Headache disorder (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/headache-disorder.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Headache disorder — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Headache disorder (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Headache disorder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Renacidin	CITRIC ACID	Baxter	Anti-coagulant		1982-01-01
Sudafed PE	phenylephrine	Generic (multiple manufacturers)	Alpha-1 adrenergic agonist (decongestant/vasopressor)	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor	1976-01-01
Aleve	naproxen	Generic (originally Syntex)	NSAID	Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1	1976-01-01
Sudafed	pseudoephedrine	Generic (multiple manufacturers)	Nasal decongestant (sympathomimetic)	Alpha-1A adrenergic receptor, Alpha-2A adrenergic receptor, Beta-2 adrenergic receptor	1976-01-01
Lithobid	lithium carbonate	Generic (multiple manufacturers)	Mood stabilizer	Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3	1970-04-06
Advil	ibuprofen	Generic (originally Boots Group)	Nonsteroidal Anti-inflammatory Drug [EPC]	Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2	1969-01-15
Acetaminophen	Paracetamol	Polymedica	acetaminophen	Transient receptor potential cation channel subfamily V member 4	1968-01-01
Delsym	dextromethorphan	Generic (originally Roche)	Antitussive (non-opioid)	Taste receptor type 2 member 46, Solute carrier family 22 member 1, Cytochrome P450 2D6	1958-01-01
Mucinex	guaifenesin	Generic (multiple manufacturers)	Expectorant [EPC]	Vagal gastric reflex → increased respiratory secretions	1952-01-01
Phenergan Vc W/ Codeine	PHENYLEPHRINE BITARTRATE	ANI Pharmaceuticals	Nonsteroidal Anti-inflammatory Drug [EPC]	Alpha-1B adrenergic receptor	1952-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Generic (multiple manufacturers) · 5 drugs in Headache disorder
· 4 drugs in Headache disorder
Baxter · 1 drug in Headache disorder
Endo · 1 drug in Headache disorder
Generic (originally Boots Group) · 1 drug in Headache disorder
Generic (originally Roche) · 1 drug in Headache disorder
Generic (originally Syntex) · 1 drug in Headache disorder
Hikma · 1 drug in Headache disorder
Polymedica · 1 drug in Headache disorder
ANI Pharmaceuticals · 1 drug in Headache disorder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Headache disorder:

Cite this brief

Drug Landscape (2026). Headache disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/headache-disorder. Accessed 2026-06-10.

Headache disorder full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing